Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

COVID19

Janssen Single-Shot COVID-19 Vaccine Gets Emergency Use Authorization

Diana Ernst, RPh

March 3, 2021

The EUA was based on data from the randomized, double-blind, placebo-controlled ENSEMBLE trial.

COVID19

Bamlanivimab Plus Etesevimab Cuts COVID-19 Hospitalization, Deaths

Diana Ernst, RPh

February 4, 2021

The combination therapy reduced the risk of hospitalization or death by 70%.

COVID19

ACIP Updates Recommendation on COVID-19 Vaccine Intervals

Diana Ernst, RPh

January 29, 2021

If keeping to the authorized schedule is not feasible, the second dose may be scheduled for administration up to 42 days (6 weeks) after the first dose, according to ACIP.

COVID19

FDA Urges HCPs to Follow Authorized Dosing Schedules for COVID-19 Vaccines

Diana Ernst, RPh

January 27, 2021

Additional research from the vaccine manufacturers would be needed to support any changes to the dosing schedule.

COVID19

Pfizer-BioNTech COVID-19 Vaccine Elicits Response Against Key Mutation

Diana Ernst, RPh

January 21, 2021

The study was conducted by Pfizer and the University of Texas Medical Branch.

COVID19

ACIP: COVID-19 Vaccine Should Be Offered to HCPs, LTC Residents First

Diana Ernst, RPh

December 8, 2020

The recommendation was made based on the number of confirmed COVID-19 cases among these 2 groups, as well as ethical and scientific considerations.

COVID19

Antibody Cocktail for COVID-19 Gets Emergency Use Authorization

Diana Ernst, RPh

November 30, 2020

The investigational treatment from Regeneron consists of 2 potent, virus-neutralizing antibodies.

COVID19

Final Analysis Reveals COVID-19 Vaccine Candidate BNT162b2 95% Effective

Diana Ernst, RPh

November 20, 2020

The analysis of the primary outcomes was based on 170 confirmed cases of COVID-19.

COVID19

Interim Data Show COVID-19 Vaccine Candidate mRNA-1273 Near 95% Effective

Diana Ernst, RPh

November 17, 2020

The placebo-controlled COVE study is investigating the efficacy and safety of mRNA-1273 at the 100mcg dose (given intramuscularly in a 2-dose series, approximately 28 days apart) in more than 30,000 adults aged 18 years and older.